Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/27/2026
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
- Nvidia forecasts 70% sales growth next year, signals AI spending boom has years left to run
- Oil settles down after choppy session as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Nutanix (NTNX) Tops Q4 EPS by 11c, Beats in Revenue; Offers Q1 Revenue Guidance
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
- Wall Street stocks end tad lower after hot inflation data ahead of Nvidia earnings
Collegium Pharma (COLL) Misses Q4 EPS by $1.77
February 24, 2022 4:30 PM ESTCollegium Pharma (NASDAQ: COLL) reported Q4 EPS of ($0.73), $1.77 worse than the analyst estimate of $1.04. Revenue for the quarter came in at $27.36 million versus the consensus estimate of $81.61 million.
For earnings history and earnings-related data on Collegium Pharma (COLL) click here.
... More